



Experimental and *in silico* studies of dichloro-tetrakis(1H-pyrazole)-cobalt(II): Structural description, photoluminescent behavior and molecular docking

Amani Direm^{a,*}, Brahim El Bali^b, Koray Sayin^c, Mohammed S.M. Abdelbaky^d, Santiago García-Granda^d

^aLaboratory of Structures, Properties and Interatomic Interactions LASPIZA, Department of Matter Sciences, Faculty of Sciences and Technology, Abbes Laghrour University Khenchela, 40.000 Algeria

^bIndependent scientist, Oujda, Morocco

^cDepartment of Chemistry, Faculty of Science, Cumhuriyet University 58140 Sivas – Turkey

^dDepartamento de Química Física y Analítica, Universidad de Oviedo-CINN, 33006 Oviedo, Spain

ARTICLE INFO

Article history:

Received 20 November 2020

Revised 20 February 2021

Accepted 5 March 2021

Available online 10 March 2021

Keywords:

Pyrazole complex

Topological analysis

Hirshfeld surface analysis

Photoluminescence

In silico study

Molecular docking

ABSTRACT

A novel pyrazole-based Co(II) complex, namely dichloro-tetrakis(1H-pyrazole)-cobalt(II), was synthesized and characterized. Its X-ray crystal structure showed that it crystallizes in the monoclinic $C2/c$ space group with discrete $[\text{CoPz}_4\text{Cl}_2]$ units held together via intra- and intermolecular hydrogen bonds. The non-covalent interactions were explicitly analyzed by means of the topological and Hirshfeld surface analyses, revealing the presence of 0-periodic binodal 1,6-connected **1,6M7-1** and 14-connected uniodal **bcu-x** topologies built up through N–H...Cl and C–H...Cl hydrogen-bonding networks in addition to weak non-classical H...H, N–H...C, C–H...N, N–H... π , π ... lp/lp ... π and lp ... lp interactions. Additionally, interactions energy and energy frameworks analyses were performed in order to compute the total energies of the possible intermolecular interactions. The empty space in the crystal lattice was analyzed using *void mapping* which lead to the presence of small cavities. The structure was furthermore optimized showing a very good agreement with the experimental results, the molecular electrostatic potential (MEP) maps were obtained with their active regions and the non-linear optical properties estimated. Additionally, the optical properties of the title complex were investigated at room temperature using optical UV-visible absorption and photoluminescence spectroscopy, exhibiting $\pi \rightarrow \pi^*$, $n \rightarrow \pi^*$, $d \rightarrow d$ and ligand-field transitions which result in a large variety of emission bands predominant by a bright red photoluminescence. An *in silico* study was carried out and the binding ability of the title complex with *Staphylococcus aureus* tyrosyl-tRNA synthetase and *Pyrococcus kodakaraensis* aspartyl-tRNA synthetase was evaluated displaying a good inhibition activity towards the last one.

© 2021 Elsevier B.V. All rights reserved.

1. Introduction

Heterocyclic compounds containing nitrogen, oxygen and sulfur, and their metal complexes are biologically active materials toward bacteria, fungi and viruses [1–5]. Especially, pyrazole-based ones, referred to hereafter as Pz, are applied in the pharmaceutical and agrochemical fields [6]. The pyrazolate ligand can exhibit three coordination modes. It can act as a monodentate (pyrazole-N) and exo-bidentate (pyrazole N,N) or an endo-bidentate ligand [7,8]. In most cases, the pyrazolate ligand coordinates in an exo-bidentate fashion, thus linking two metal centres that may be identical or

different. Recent studies have described the catalytic activity of pyrazolate complexes [8,9] under mild conditions, thus encouraging the exploration of these ligands.

In fact, since the first review of pyrazole-derived ligands appeared in 1972 [10], the coordination chemistry of Pz and its derivatives has strongly evolved over the last two decades [11]. Pz derivatives have many other applications such as analgesic [12], antibacterial [13], anti-hyperglycemic [14], anti-inflammatory [15], antipyretic [16], hypoglycaemic [17] and sedative hypnotic activities [18]. The ones such as *celecoxib*, *rimonabant*, *fomepizole* and *sildenafil* were established as selective drugs [19]. In fact, *celecoxib* demonstrated anti-inflammatory effect and inhibited *cox-2* [20], while *rimonabant* is a cannabixiod receptor and is used for obesity treatment. *Bindenafil* and *fomepizole* inhibit phosphodiesterase

* Corresponding author.

E-mail address: amani_direm@yahoo.fr (A. Direm).